Dyne reports Q3 2026 results as z-rostudirsen BLA review continues toward January 2027 decision
FDA review of the Duchenne therapy carries a PDUFA date of January 21, 2027, while Dyne also reported new one-year DM1 data and $1.134 billion in cash.
SEC filing